What is Novavax's revenue?

Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.

Is Novavax profitable?

Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.

What are Novavax's profit margins?

Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.

What is Novavax's earnings per share?

Novavax's diluted EPS over the trailing twelve months is $-0.64.

Where does Novavax's income statement data come from?

Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Novavax NVAX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$1.12B+64.7%	$682.16M-30.7%	$983.71M-50.4%	$1.98B+72.9%
Total cost of revenue	$73.04M-64.0%	$202.74M-41.0%	$343.77M-61.9%	$902.64M—
Gross profit	$1.05B+119%	$479.42M-25.1%	$639.94M-40.7%	$1.08B-5.8%
Gross margin	93.5%+23.2pp	70.3%+5.2pp	65.1%+10.6pp	54.5%-45.5pp
Research and development	$342.32M-12.5%	$391.17M-47.0%	$737.5M-40.3%	$1.24B-51.3%
Selling, general and administrative	$157.48M—	——	$468.95M-4.0%	$488.69M—
Total costs & expenses	$670.68M-28.0%	$931.09M-39.9%	$1.55B-41.0%	$2.63B-7.3%
Operating income	$452.8M+282%	-$248.93M+56.1%	-$566.51M+12.1%	-$644.74M+61.8%
Operating margin	40.3%+76.8pp	-36.5%+21.1pp	-57.6%-25.1pp	-32.5%+115pp
Interest expense	$22.55M+12.3%	$20.08M+39.3%	$14.42M-27.5%	$19.88M-5.9%
Other income (expense), net	$40.63M+0.5%	$40.44M+6.7%	$37.9M+245%	$10.97M+251%
Income before income taxes	$442.17M+350%	-$176.62M+67.5%	-$543.03M+16.9%	-$653.65M+61.9%
Income tax expense	$1.87M-82.9%	$10.88M+436%	$2.03M—	——
Net income	$440.3M+335%	-$187.5M+65.6%	-$545.06M+17.2%	-$657.94M+62.3%
Net margin	39.2%+66.7pp	-27.5%+27.9pp	-55.4%-22.2pp	-33.2%+119pp
Diluted earnings per share	$2.35+275%	-$1.34+75.9%	-$5.56+33.9%	-$8.41+64.1%
EBITDA	$480.41M+340%	-$200.44M+61.8%	-$525.29M+14.7%	-$615.68M+63.2%
EBITDA margin	42.8%+72.1pp	-29.4%+24.0pp	-53.4%-22.3pp	-31.1%+115pp
EBIT	$452.8M+282%	-$248.93M+56.1%	-$566.51M+12.1%	-$644.74M+61.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Novavax.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's revenue?: Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
Is Novavax profitable?: Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
What are Novavax's profit margins?: Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
What is Novavax's earnings per share?: Novavax's diluted EPS over the trailing twelve months is $-0.64.
Where does Novavax's income statement data come from?: Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.